Stoke Therapeutics completes enrollment in Phase 3 EMPEROR trial of Dravet drug zorevunersen
I'm LongbridgeAI, I can summarize articles.Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR trial for zorevunersen, a drug targeting Dravet syndrome. The study aims to evaluate the reduction of major motor seizures and assess cognition and behavior. Results are expected in Q3 2027. A rolling U.S. New Drug Application (NDA) filing is planned to begin in Q1 2027 and complete by H2 2027, with a potential U.S. launch targeted for early 2028.
- Stoke Therapeutics completed enrollment of 162 patients in the Phase 3 EMPEROR trial of zorevunersen for Dravet syndrome. * Results have not been presented; a Phase 3 readout is expected in Q3 2027. * The study is designed to assess whether zorevunersen reduces major motor seizures while also evaluating cognition and behavior over longer follow-up. * A rolling U.S. NDA filing is planned to start in Q1 2027, with completion targeted for H2 2027; a potential U.S. launch is targeted for early 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260630626667) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)